Company Encyclopedia
View More
name
Connect Biopharma
CNTB.US
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company’s lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
1.876 T
CNTB.USMarket value -Rank by Market Cap -/-

Financial Score

14/11/2025 Update
D
BiotechnologyIndustry
Industry Ranking273/389
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-66.80%E
    • Profit Margin-6466.80%E
    • Gross Margin100.00%A
  • Growth ScoreE
    • Revenue YoY-96.96%E
    • Net Profit YoY-131.34%E
    • Total Assets YoY-33.49%E
    • Net Assets YoY-39.92%E
  • Cash ScoreE
    • Cash Flow Margin-1.55%D
    • OCF YoY-96.96%E
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreA
    • Gearing Ratio17.80%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Connect Biopharma (NASDAQ:CNTB) Announces Earnings Results, Misses Estimates By $0.07 EPS

    Connect Biopharma (NASDAQ:CNTB) reported a quarterly earnings per share (EPS) of ($0.31), missing analysts' estimates by $0.07. Despite the earnings miss, the stock traded up 4.3% to $1.59. The company has a market cap of $88.32 million and a P/E ratio of -3.77. Analysts have mixed ratings on the stock, with a consensus target price of $7.00. Institutional investors, including XTX Topco Ltd, hold 58.72% of the stock.

    Market Beat·
    US
    CNTB
    +26.19%
    Market Beat·
    US
    CNTB
    +26.19%

    Buy Rating for Connect Biopharma Holdings: Rademikibart’s Market Differentiation and Safety Advantages

    Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating for Connect Biopharma Holdings with a $7.00 price target, citing the potential of their product, Rademikibart, in treating asthma and COPD. Rademikibart's market differentiation and safety advantages, such as not increasing eosinophil counts, support this rating. BTIG also initiated coverage with a Buy rating and a $10.00 price target.

    Tip Ranks·
    US
    CNTB
    +26.19%
    Tip Ranks·
    US
    CNTB
    +26.19%

    Connect Biopharma | 10-Q: FY2025 Q3 Revenue: USD 16 K

    LB filings·
    US
    CNTB
    +26.19%
    LB filings·
    US
    CNTB
    +26.19%

    Connect Biopharma | 8-K: FY2025 Q3 Revenue: USD 16 K

    LB filings·
    US
    CNTB
    +26.19%
    LB filings·
    US
    CNTB
    +26.19%

    Connect Biopharma Reports Q3 2025 Results and Advances Rademikibart Clinical Programs

    Connect Biopharma Holdings Ltd. reported its Q3 2025 financial results, highlighting ongoing recruitment for Phase 2 Seabreeze STAT studies on rademikibart for asthma and COPD, with topline data expected in H1 2026. In China, Simcere submitted a New Drug Application for rademikibart for atopic dermatitis, accepted by the National Medical Products Administration. The company also terminated its American Depositary Receipt program and listed its shares on Nasdaq under "CNTB". As of September 30, 2025, it had $54.8 million in cash and equivalents, sufficient to fund operations into 2027.

    Reuters·
    US
    CNTB
    +26.19%
    Reuters·
    US
    CNTB
    +26.19%